Lifecare ASA

Regulatory Filings • Jun 4, 2024

LIFE: Lifecare ASA has filed application for a new patent

LIFE: Lifecare ASA has filed application for a new patent

Bergen, Norway, June 4th, 2024: Today, Lifecare ASA (LIFE), a clinical stage

medical sensor company developing the next generation Continuous Glucose

Monitor (CGM), announces that the company has filed an application for a new

patent to the European Patent Office (EPO).

Reference is made to previous communication of the potential of the sensor

technology beyond glucose measurements, which the company focuses on today.

For use in Lifecare's already patented and proprietary technology utilizing

osmotic pressure as glucose sensor principle, the Company has developed a new

conceptual chemistry composition including modular receptor molecules for

detection of a wide range of diseases or conditions.

The chemistry invention comprises different receptors (cellular, biological,

artificial and synthesized, oligonucleotides, inorganic receptor layers or the

like) to induce changes in the osmotic pressure. The purpose of the invention

is to identify and/or monitor diseases or conditions of acute or chronic

disorders, such as cardiovascular disease, metabolic disorders, infections,

immune diseases or the like, in addition to Lifecare's primary focus on

diabetes.

The patent-filing indicates that Lifecare is developing towards a broader

reach as a sensor company, beyond monitoring of glucose. While the Company's

focused mission is to provide better solutions for people with diabetes, the

patent-filing is very much aligned with Lifecare's main goal to improve lives

through medical technology. The patent-filing is a confirmation of the

ambitions as a sensor company based on a platform technology applicable to

identify and/or monitor a broad range of diseases or conditions of acute or

chronic disorders.

The development is a result of innovative research and development at Lifecare

Chemistry Ltd. (Bristol, UK), a fully owned subsidiary of Lifecare ASA.

Lifecare Chemistry was established in 2022 as a development unit with the main

task to improve the chemistry compositions for glucose detection, in

particular the sensing sensitivity, and to accelerate Lifecare's intention to

develop a modular system for detection and/or monitoring of various analytes

beyond glucose. The subsidiary is led by Dr. Jordan Edward Gardiner, while

Professor Tony James at the University of Bath acts as an important expert

consultant in chemistry development.

-It is an important achievement for Lifecare to file this patent application.

We are strongly committed to bringing our Continuous Glucose Monitor to the

veterinary and human market. In addition, we believe that our sensor principle

and sensor hardware have great opportunities beyond glucose monitoring, and we

must ensure appropriate protection of this broad potential. The new innovation

is expected to both, further improvement of our glucose measurement

capacities, as well as being a door opener for measurements in other areas

with high commercial interest, says CEO Joacim Holter at Lifecare ASA.

Previously granted patent from EPO:

March 21st, 2024, Lifecare announced that EPO had granted a new patent to

Lifecare. The patent was related to chemistry compositions and method for

preparing the composition and use, specifically of Lifecare's original and

proprietary fluid composition reactive to glucose. This active fluid enables

monitoring of glucose in Lifecares miniaturized sensor-technology, by the

means of osmotic pressure as the sensing principle and is improving:

* sensor lifetime

* measurement response time

* measurement sensitivity

About us

Lifecare ASA is a clinical stage medical sensor company developing technology

for sensing and monitoring of various body analytes. Lifecare's main focus is

to bring the next generation of Continuous Glucose Monitoring ("CGM") systems

to market. Lifecare enables osmotic pressure as sensing principle, combined

with the ability to manipulate Nano-granular Tunnelling Resistive sensors

("NTR") on the sensor body for read-out of pressure variations. Lifecare's

sensor technology is referred to as "Sencell" and is suitable for identifying

and monitoring the occurrence of a wide range of analytes and molecules in the

human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42